ePrints

A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) +/- lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)

Lookup NU author(s): Professor Michael Griffin, Dr Kate Sumpter

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Smyth E, Rowley S, Allum W, Stenning S, Wotherspoon A, Robb C, Grabsch H, Alderson D, Crosby T, Mason R, Griffin M, Mansoor W, Darby S, Seymour M, Thompson J, Sothi S, Sumpter K, Blazeby J, Langley R, Cunningham D

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 41st ESMO Congress (ESMO 2016)

Year of Conference: 2016

Pages: LBA26

Print publication date: 01/10/2016

Online publication date: 13/10/2016

Acceptance date: 02/04/2016

ISSN: 0923-7534

Publisher: Oxford University Press

URL: https://doi.org/10.1093/annonc/mdw435.17

DOI: 10.1093/annonc/mdw435.17

Share